NBI-1065845 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Treatment Resistant Depression. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of NBI-1065845’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for NBI-1065845 is expected to reach an annual total of $30 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NBI-1065845 (TAK-653) is under development for major depressive disorder (MDD), treatment-resistant depression (TRD). It is administered orally as a tablet. It acts by targeting AMPA receptor. It was also under development for the treatment of neurological diseases. The drug candidate is a new molecular entity.
Neurocrine Biosciences Overview
Neurocrine Biosciences (Neurocrine) discovers, develops, and sells pharmaceutical products for the treatment of neurologic, psychiatric, and endocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). The company’s other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids, and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. The company also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$1,488.7 million for the fiscal year ended December 2022 (FY2022), an increase of 31.3% over FY2021. The operating profit of the company was US$179 million in FY2022, compared to an operating profit of US$102.5 million in FY2021. The net profit of the company was US$154.5 million in FY2022, compared to a net profit of US$89.6 million in FY2021.
For a complete picture of NBI-1065845’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.